SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: A.J. Mullen who wrote (19683)4/7/2006 11:29:52 PM
From: scaram(o)uche  Read Replies (1) | Respond to of 52153
 
As you witnessed, the "elapsed time" issue is what would occur IMMEDIATELY to any cellular immunologist.....

Message 22262931

For this particular antibody, it is mind-boggling dumb that a sufficient period of time was not allowed between the various patients......... the unknown world of agonists.

There was a real disconnect here. The individual who designed this injection schedule needed to talk to a few bench grunts.



To: A.J. Mullen who wrote (19683)4/8/2006 1:29:29 AM
From: zeta1961  Respond to of 52153
 
Ashley, I really didn't buy for a minute that the co. would be careless preclinically but it's assuring to know from those close to it outside of the media. This is a brave new world..interferon was still experimental during my peak years..talk about dating myself..Terms that we throw around here were barely yet invented..leukotrines?..cytokines?..

Elisabeth


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News